Skip to content
Life Sciences Series A Founded 2020

Tagomics

Developer of genomic-based cancer diagnostic platform. It offers a platform technology based on a non-invasive blood test that captures the unmodified locations of the genome and analyzes the changes that occur during cancer. The company was founded in 2020 and headquartered in Birmingham, United Kingdom. It has raised $8.4M in series a funding, with backing from Calculus Capital, Illumina Ventures, IQ Capital,…

📍 Birmingham, United Kingdom · Oncology,

Funding snapshot

Last roundSeries A
Amount$1M
Date10 June 2025
Total raised$8M
Valuation20,319,780 (May 9, 2025)
Team size26

About

Developer of genomic-based cancer diagnostic platform. It offers a platform technology based on a non-invasive blood test that captures the unmodified locations of the genome and analyzes the changes that occur during cancer. The company was founded in 2020 and headquartered in Birmingham, United Kingdom. It has raised $8.4M in series a funding, with backing from Calculus Capital, Illumina Ventures, IQ Capital, Agilent, and others. The company operates in the Life Sciences - Oncology, Life Sciences - Genomics, Life Sciences - Clinical Genomics space. Its offerings span Oncology - In-Vitro Diagnostic Tests - Diversified. The company's offerings encompass Oncology - In-Vitro Diagnostic Tests - Diversified.

Business model

Oncology > In-Vitro Diagnostic Tests > Diversified,

Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Genetic Diagnosis > Epigenomics

Institutional investors

Calculus Capital Illumina Ventures IQ Capital Agilent Mercia Midlands Engine Investment Fund Meltwind Advisory OMX Ventures Ukri

Latest coverage

No articles yet.

Raising like Tagomics?

Analyze your pitch deck before your next raise.

Analyze My Deck →